Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
57.26 USD | +2.54% |
|
+7.35% | +108.22% |
Jul. 08 | Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate | MT |
Jul. 08 | Merus Initiates Mid-stage Study of Colorectal Cancer Combination Therapy | MT |
Business Summary
Number of employees: 201
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Therapeutics
100.0
%
| 42 | 100.0 % | 44 | 100.0 % | +5.68% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Netherlands
100.0
%
| 42 | 100.0 % | 44 | 100.0 % | +5.68% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Bill Lundberg
CEO | Chief Executive Officer | 60 | 19-06-11 |
Gregory Perry
DFI | Director of Finance/CFO | 63 | 16-04-30 |
Chief Tech/Sci/R&D Officer | - | 16-11-30 | |
Chief Tech/Sci/R&D Officer | 56 | 21-04-30 | |
Peter Silverman
COO | Chief Operating Officer | 46 | 17-01-31 |
John de Kruif
CTO | Chief Tech/Sci/R&D Officer | 60 | 07-03-31 |
Sherri L. Spear
IRC | Investor Relations Contact | - | - |
Ashley Pereira
LAW | General Counsel | - | 21-08-31 |
Shannon Campbell
PRN | Corporate Officer/Principal | 58 | 22-01-31 |
Harry Shuman
AUD | Comptroller/Controller/Auditor | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gregory Perry
DFI | Director of Finance/CFO | 63 | 16-04-30 |
Maxine Gowen
BRD | Director/Board Member | 66 | 21-05-27 |
Paolo Pucci
BRD | Director/Board Member | 63 | 20-06-29 |
Anand Mehra
CHM | Chairman | 48 | 15-08-25 |
Mark Iwicki
BRD | Director/Board Member | 57 | 15-04-30 |
Bill Lundberg
CEO | Chief Executive Officer | 60 | 19-06-11 |
Victor Sandor
BRD | Director/Board Member | 57 | 19-06-11 |
Jason Haddock
BRD | Director/Board Member | 54 | May. 06 |
Len Kanavy
BRD | Director/Board Member | 62 | 18-06-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 67,370,051 | 62,983,844 ( 93.49 %) | 0 | 93.49 % |
Company contact information
![address Merus N.V.(MRUS)](https://cdn.zonebourse.com/static/address/27548017.png)
Sector
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+108.22% | 3.79B | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- MRUS Stock
- Company Merus N.V.